ASH 2021

Part II: CAR-T cells - all over the field data for…

Prevention of CNS relapse after R-CHOP

Axi-cel - new standard for r/r LBCL patients?

HD-MTX does not lower SCNS rates in high-risk patients

Tisa-cel - new CAR-T option for R/R aNHL

pola-R-CHP vs. R-CHOP: a new standard?

pola-R-CHP vs. R-CHOP: Neuer Standard?

La prevenzione della recidiva a carico del sistema…

Axi-Cel I Tisa-Cel I Liso-Cel: Drei neue CAR-T-Optionen…

Part I: Potential change in first-line treatment?

Encouraging real world safety and efficacy data of…

HiDAC-containing induction before ASCT substantially…

Maintenance with Rituximab-Lenalidomid (R2)

Low-dose lenalidomide added to rituximab maintenance in…

Pirtobrutinib - promising agent moving forward

Focus on maintenance is critical in MCL

Glofitamab SUD as monotherapy after Gpt induced high…

Pirtobrutinib shows promising efficacy and safety in…

Añadir lenalidomida a dosis bajas a rituximab en el…

Pirtobrutinib es eficaz y seguro en pacientes muy…

Pirtobrutinib: Neuer, nicht-kovalenter BTKi

La inducción con citarabina a dosis altas antes del…

Ruolo del mantenimento con R2 nel linfoma mantellare

Rituximab-Lenalidomid Erhaltungstherapie (R2)

Part II: Bi-specific antibodies as an attractive agent

MRD monitoring in follicular lymphoma is extremely…

Active new therapy for 3L+ R/R FL

First-line options and RM

Mosunetuzumab + Lenalidomid beim r/r FL

Rituximab-Erhaltung nach ICT bleibt Standard

Part I: Promising data in CLL

Pirtobrutinib - promising efficacy in heavily…

NDMM: On the way to cure?

The immunotherapy tsunami continues - bispecific…

The immunotherapy tsunami continues - CAR-T cells

PFS separation in the Griffin trial

Positive results for high-risk myeloma from the UK

Quadruple therapy - the treatment of choice in NDMM

Quadruple regimens for NDMM

Triplet therapie in elderly patients

No benefit for elotuzumab in NDMM

Isatuximab + RVd erfogreich, Elotuzumab nicht

Quadrupletts Dara-VTd bzw. Dara-RCd erste Optionen bei…

PFS separation in the Griffin trial

New bispecific antibodies and CAR-T cells for RRMM…

talquetamab & cevostamab: bispecific antibodies beyond…

TAK-573 - a really new mechanism of treatment in…

cilta-cel: early, deep and durable responses in heavily…

Not another BCMA drug

Is CAR-T cell treatment better in heavly pretreated…

Update on bispecific antibody teclistamab

KRd consolidation reverses PET positivity in 1/3 of the…

cilta-cel highly effective in heavily pretreated…

Elranatamab - a new bispecific antibody in RRMM

New bispecific antibodies and CAR-T cells for RRMM…

Talquetamab und Cevostamab: Neue bispezifische Ak…

cilta-cel: frühes, tiefes, lang anhaltendes Ansprechen…

Bispezifischer Antikörper Teclistamab beim r/r MM

CAR-T oder bispezifische MoAk in der Rezidivtherapie -…

TAK-573 - a really new mechanism of treatment in…

KRd consolidation reverses PET-positivity in 1/3 of the…

MGUS and COVID-19 risk

New reference values for light chains in multiple…

Myeloma precurser disease 2021

Prävalenz und Risikostratifikation beim SMM